Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

hVIVO to develop first commercial hMPV human challenge model

hVIVO PLC

hVIVO PLC (AIM:HVO) chief executive Mo Khan speaks to Thomas Warner from Proactive after announcing that the specialist contract research organisation has partnered with a North American biopharmaceutical company to create the industry's first commercial hMPV human challenge model. Khan says he's "very happy with the signing of this contract" before going to explain the significance of the news for hVIVO investors as well as for patients. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

June 28, 2023 07:42 AM Eastern Daylight Time

Video

ImmuPharma "absolutely delighted" to push on with new clinical trial

ImmuPharma PLC

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive Tim McCarthy visited Thomas Warner at the Proactive London studio after confirming to the market that the specialty biopharmaceutical will be moving forward into a key phase 2/3 adaptive clinical trial, alongside its US partners Avion Pharmaceuticals. McCarthy says that he's "absolutely delighted" to be moving forward with the study and emphasises the significant potential of its deal with Avion, including milestone payments of up to $70 million and double-digit royalty percentages, in addition to obvious benefit to patients. McCarthy also mentions ongoing discussions for more commercial partnerships and the potential for major breakthroughs in the future. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

June 28, 2023 07:37 AM Eastern Daylight Time

Video

'Siblings of the Exceptional’: Empowering Siblings of the Special Needs Children And Creating Lasting Impact

Siblings of the Exceptional

'Siblings of the Exceptional,' an organization dedicated to supporting siblings of special needs children, is making a significant difference in the community. Founded by Reema Patel, a 14-year-old American girl and rising sophomore, the organization focuses on raising awareness, providing resources and fostering inclusion for siblings of individuals with Cerebral Palsy and other special needs as well as their families. By emphasizing the organization’s goals and achievements it brings positive changes to the community and showcases the collective effort in supporting siblings of special needs. This approach allows them to promote a cause and create awareness about siblings of special needs within the community. According to recent statistical data by WHO, an estimated 1.3 billion people - or 16% of the global population worldwide - experience a significant disability today. People with disabilities have the right to the highest attainable standard of health as those without disabilities. However, the WHO Global report on health equity for people with disabilities demonstrates that while some progress has been made in recent years, the world is far from realizing this right for many people with disabilities, because they continue to die earlier, have worse health, and experience more limitations in everyday functioning than others. These poor health outcomes are due to unfair conditions faced by people with disabilities in all facets of life, including the health system in many countries. Countries have an obligation under international human rights law to address the health inequities faced by people with disabilities. Furthermore, the Sustainable Development Goals and global health priorities will not progress without ensuring health for all. Recognizing the significance of these numbers and the impact on families, Reema took it upon herself to provide a platform for siblings of these exceptional children to connect, share experiences, and find solace in a nurturing community. Through the efforts of 'Siblings of the Exceptional,' strides are being made to address these statistics, improve the lives of special needs children as well as their siblings and promote a more inclusive society. The Initiative to Bond special needs with Their Siblings ‘Siblings of the Exceptional' also focuses on fostering a special bond among special needs children and their siblings. Recognizing the importance of these relationships, the organization arranges events and programs that promote a stronger bond between the children with special needs and their siblings. By doing so, they create a supportive and inclusive environment for special needs and their families. The latest event took place on June 24th, 2023 in Pune, India where a generous amount of resources were donated by Reema Patel to the Buddy Center institute which is an initiative by Kunashini. The esteemed chief Guest, Dr Archana Kadam, praised Reema Patel's extraordinary efforts and offered valuable insights on raising awareness about Cerebral palsy and special needs. The event served as a platform to foster a sense of community and create lasting memories. Fundraising Efforts To date, 'Siblings of the Exceptional' has successfully raised approximately US $9,740. These funds have been instrumental in supporting numerous NGOs in India that work tirelessly to meet the basic needs of special needs children, providing them with vital resources, therapies, and a nurturing environment. This highlights the impact and effectiveness of the organization's fundraising efforts. The World too can join the Cause of 'Siblings of the exceptional". The dynamic Reema Patel passionately appeals to individuals, organizations, and a wider community to support the noble causes of 'Siblings of the Exceptional.' Donations and fundraising efforts play a pivotal role in enabling the provision of essential resources and services to special needs children in need. By contributing to the cause, you can make a tangible difference in their lives. To learn more about this inspiring journey, contribute to her cause, or participate in upcoming events, please visit 'Siblings of the Exceptional' at https://www.siblingsoftheexceptional.com/. Contact Details Siblings of the Exceptional Reema Patel +1 540-558-8784 dreamsforspecialfamilies@gmail.com Company Website https://www.siblingsoftheexceptional.com/

June 27, 2023 11:00 AM Eastern Daylight Time

DSS Inc. Is Spinning Off Its Biotech Subsidiary After Signing A Major Licensing Agreement

DSS, Inc.

By David Willey, Benzinga DSS, Inc. (NYSE American: DSS) is finalizing the long-anticipated spin-off of its biotech subsidiary, Impact Biomedical, Inc. The spin-off will reward DSS investors with shares from Impact, and it will come after an Impact subsidiary signed a licensing agreement with a pharmaceutical company. Investors who own DSS shares as of June 30 will receive four (4) Impact Biomedical shares for every one of their DSS shares, as part of the spin-off. The spin-off is coming after Impact Biomedical’s subsidiary, Global BioLife, Inc., signed a licensing agreement with ProPhase BioPharma, Inc., a subsidiary of ProPhase Labs, Inc. (NASDAQ: PRPH) for Global BioLife’s Linebacker portfolio of treatments, LB-1 and LB-2. Prophase Labs is a growing diagnostic, genomics and biotech company with a diversified portfolio. Impact’s Success In Biotech Linebacker is a platform of small molecule X-bonded polyphenols, and LB-1 and LB-2 are treatments that are expected to be effective in crossing the blood-brain barrier. Linebacker could prove to be a treatment with a range of applications, including in neurology, anti-inflammatory and oncology diseases. With this licensing agreement, ProPhase will continue developing Linebacker as a potential therapeutic. In fact, on June 1, ProPhase announced that “Harvard scientists at the Dana Farber Cancer Institute, in two separate lung and colon cancer clonogenic models, have successfully demonstrated Linebacker’s ability to inhibit cancer cell growth, an exciting development for the polyphenol compound.” The company already believes that LB-1 may be an effective therapy for hard-to-treat cancers and other types of cancer. Frank D. Heuszel, CEO of DSS, commented on the agreement, “The execution of this licensing agreement represents a significant milestone for Impact BioMedical and its robust portfolio of development opportunities. This is the second license agreement with ProPhase this year, and we are excited to deepen our work together as they apply their nearly three decades of experience enhancing the health of the public.” Ted Karkus, ProPhase Lab's CEO, commented on the partnership in July 2022, “We believe the Linebacker platform has multi-billion-dollar potential in oncology as well as significant potential in other fields.” 4 Shares In Spin-Off For Every DSS Share DSS could offer a potentially lucrative opportunity to investors looking to diversify their portfolios. This is not the only spin-off opportunity that DSS will offer, as the company operates nine divisions and 40 subsidiaries. DSS has plans to spin off two other of its successful subsidiaries later in 2023. These are the medical real estate investment trust, AAMI/AMRE, as well as the financial services company, American Pacific Bancorp. By incubating and eventually spinning off companies, DSS develops companies like Impact Biomedical to increase shareholder value. All shareholders of record on June 30, will receive four (4) shares in Impact Biomedical to be distributed on July 14. Learn more about what DSS, Inc. is doing to support and spinoff businesses. DSS is a multinational company operating businesses within nine divisions: Product Packaging, Biotechnology, Direct Marketing, Commercial Lending, Securities and Investment Management, Alternative Trading, Digital Transformation, Secure Living, and Alternative Energy. DSS strategically acquires and develops assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy. Since 2019, under the guidance of new leadership, DSS has built the necessary foundation for achievable growth through the formation of a diversified portfolio of companies positioned to drive profitability in multiple high growth sectors. These companies offer innovative, flexible, and real-world solutions that not only provide mutual benefits for businesses and their customers, but also create sustainable value and opportunity for transformation. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice Contact Details Rick Lutz- TraDigital IR rick@tradigitalir.com Company Website https://www.dssworld.com/

June 27, 2023 09:15 AM Eastern Daylight Time

Roquefort Therapeutics "seeing good results" across several therapeutics

Roquefort Therapeutics PLC

Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) chief executive Ajan Reginald speaks to Thomas Warner from Proactive following a flurry of announcements from the biotech company. Reginald gives an overview of three recent developments, including the results of trials into treatments for osteosarcoma and Midkine-expressing cancers. He also highlights recent increases in the level of investment in the company by himself and by executive chairman Stephen West. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

June 27, 2023 08:32 AM Eastern Daylight Time

Video

Goodbody Health "excited about where the business is going"

Goodbody Health Ltd

Goodbody Health Ltd (OTCQB:GDBYF) group CEO George Thomas speaks to Thomas Warner from Proactive about the latest developments from the wellness and diagnostic services business. Thomas says that he's "excited about where the business is going" and highlights various products either launched recently or soon to be hitting the market. He also addresses the decision to de-list from the Aquis exchange and discusses the sale of Goodbody's CBD manufacturing facility in Poland. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

June 27, 2023 06:19 AM Eastern Daylight Time

Video

Immunic Therapeutics shares IMU-856 mode of action and target for gastrointestinal diseases

Immunic Inc

Immunic Therapeutics Chief Scientific Officer Hella Kohlhof joins Natalie Stoberman from the Proactive newsroom to share the recently released mode of action, molecular target, preclinical data for its IMU-856 asset that targets restoration of intestinal barrier function and bowel wall architecture. Immunic is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), currently in phase 3 clinical trials for the treatment of multiple sclerosis, has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and moderate-to-severe ulcerative colitis. IMU-856 is targeted to restore intestinal barrier function and regenerate bowel epithelium, which would be applicable in numerous gastrointestinal diseases, such as celiac disease, where it is currently in preparations for a phase 2 clinical trial. Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com

June 26, 2023 03:44 PM Eastern Daylight Time

Video

American Businesses Want Secure Borders and a Modernized Immigration System to Help Address Worker Shortages

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/cyDh_POE9fg There might as well be a giant “Help Wanted!” sign over the United States. The economy has bounced back from the pandemic lows, but companies have been struggling to meet their workforce needs to keep up with the surge in demand for everything from household products to cars. At the same time, the crisis level situation on our southern border is not abating, as the U.S. Border Patrol has seen 133,000 more border crossings through April of this fiscal year than during the same period of time in last year’s record-shattering totals. The U.S. currently has approximately 10.1 million job openings, while there are 6 million people unemployed and looking for work. The worker shortfall has also emerged as a key factor driving persistent inflation and higher interest rates. Securing our borders and modernizing our immigration system can help us confront these challenges. Many people wonder given the seriousness of these issues and the polarization in Congress if any real progress can be achieved on border security and immigration reform? The U.S. Chamber of Commerce believes not only that it can be done, but that it must be done. The immigration challenges we face today didn’t arrive at our doorstep overnight; they’ve been around for decades and have only grown in size and severity due to many years of congressional inaction. The U.S. Chamber of Commerce is leading the LIBERTY Campaign (Legal Immigration and Border Enforcement Reform This Year) with over 430 national, state, and local business associations. The campaign launched with a letter calling upon Congress to address the crisis at our border and the critical workforce shortage before the year’s end. Many experts believe that expanding legal immigration to the U.S. would help spawn economic output by driving much needed labor force growth at a time when America’s population growth is stagnating. A nationwide media tour was conducted on June 20 th featuring Neil Bradley from the U.S. Chamber of Commerce, discussing why Congress cannot afford to wait any longer to secure our borders and modernize our broken immigration system. Topics that Neil Bradley from the U.S. Chamber of Commerce discussed included: How serious our border and legal immigration problems are. What the consequences will be if Congress foregoes fixing the problems on our borders and within our legal immigration system. How a modern, pro-growth immigration system will help address the chronic workforce issues plaguing many American employers today and other economic problems we’re suffering from. Why the Chamber launched the LIBERTY Campaign with over 430 other associations. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

June 26, 2023 03:00 PM Eastern Daylight Time

Video

Sevita Appoints Philip Kaufman as new CEO

Sevita

Sevita, a leading national provider of community-based health care and support services, has announced Philip Kaufman as its new Chief Executive Officer. Kaufman is an established executive whose leadership career has spanned two decades with UnitedHealth Group, most recently as Chief Growth Officer and CEO of UnitedHealthCare Individual and Family Plans. While there, he led initiatives focused on targeted and personalized programs to improve care coordination, decrease disparities in care, and reduce medical costs – all part of UnitedHealth’s mission to help people live healthier lives and to make the health system work better for everyone. “On behalf of everyone at Sevita, I’m thrilled to welcome Philip to our organization,” said Alan Wheatley, executive chair of Sevita’s Board of Directors. “Philip is mission-oriented and cares deeply about improving quality of life for people of all backgrounds. As a leader, he values strong relationships and a collaborative spirit, which is foundational to the person-centered work we do. I’m confident he will steward Sevita toward an even brighter future.” Sevita serves 55,000 individuals in 41 states, providing adults, children, and their families innovative, quality services and supports that lead to growth and independence, regardless of the physical, intellectual, or behavioral challenges they face. This includes residential care and periodic care services for individuals with intellectual and developmental disabilities; rehabilitation services for neurological injuries, illnesses, and other complex health needs; therapeutic and medically complex foster care; behavioral health supports; and clinically supported adult day health programs. “I’m excited to join this impactful organization and support the incredible work being done to help people with intellectual and developmental disabilities and other complex health needs to live more independently in their homes and communities,” Kaufman said. “Sevita has been a leader in this industry for nearly 50 years and has both the vision and expertise to provide solutions that expand access to the quality supports and services that millions of Americans need. I look forward to being part of its next chapter and driving progress for our business, our industry, and most importantly, our communities.” About Sevita Sevita is a leading provider of community-based specialized health care, inspired by our core values of respect, integrity, inclusion and growth. We provide people with quality services and individualized supports that lead to growth and independence, despite the physical, intellectual, or behavioral challenges they face. We’ve made this our mission for more than 50 years. Today our team members continue to innovate and enhance care for the 55,000 individuals we serve. sevitahealth.com Contact Details Melissa Patricio media@sevitahealth.com Company Website https://sevitahealth.com/

June 26, 2023 10:00 AM Eastern Daylight Time

Image

1 ... 110 111 112 113 114 ... 301